• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Lifeward Ltd. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    6/26/25 4:30:14 PM ET
    $LFWD
    Industrial Specialties
    Health Care
    Get the next $LFWD alert in real time by email
    false000160796200-0000000Floor 6Yokneam IlitIL+508.251.11544.959.0123Ordinary Shares, par value NIS 0.25NASDAQ00016079622025-06-252025-06-25


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    FORM 8-K

    CURRENT REPORT
    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
     
    Date of Report (Date of earliest event reported): June 25, 2025
     
    Lifeward Ltd.

    (Exact Name of Registrant as Specified in its Charter)
      
    Israel
     
    001-36612
     
    Not Applicable
    (State or Other Jurisdiction of Incorporation)
     
    (Commission File Number)
     
    (IRS Employer Identification No.)

    200 Donald Lynch Blvd. Marlborough, MA
     
    01752
    (Address of principal executive offices)
     
    (Zip Code)
     
    Registrant’s telephone number, including area code: +508.251.1154
      
    Not applicable
    (Former name or former address, if changed since last report)

    Securities registered pursuant to Section 12(b) of the Act:

    Title of each class
     
    Trading Symbol
     
    Name of each exchange on which registered
    Ordinary Shares, par value NIS 1.75
     
    LFWD
     
    Nasdaq Capital Market

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
     
     
    ☐
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
     
    ☐
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
     
    ☐
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
     
    ☐
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
      
    Emerging growth company ☐
     
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
     

    Item 1.01 Entry Into a Material Definitive Agreement

    Securities Purchase Agreement

    On June 25, 2025, Lifeward Ltd. (the “Company”) commenced a best efforts public offering (the “Offering”) of an aggregate of (i) 4,000,000 ordinary shares, par value NIS 1.75 per share, of the Company (“Ordinary Shares”) and (ii) 4,000,000 warrants (the “Ordinary Warrants”) to purchase up to 4,000,000 Ordinary Shares (the “Ordinary Warrant Shares”). Each Ordinary Share was sold together with one Ordinary Warrant to purchase one Ordinary Share. The combined offering price for each Ordinary Share and accompanying Ordinary Warrant was $0.65. Each Ordinary Warrant has an exercise price of $0.65 per Ordinary Share, is immediately exercisable upon issuance, and will expire on the five-year anniversary of the date of issuance.

    The net proceeds of the Offering, after deducting the fees and expenses of the Placement Agent (as defined below), described in more detail below, and other offering expenses payable by the Company, but excluding the net proceeds, if any, from the exercise of the Ordinary Warrants, are expected to be approximately $2.0 million. The Company intends to use the net proceeds from the Offering for continuing commercial efforts, working capital, and general corporate purposes. The Offering closed on June 26, 2025.

    In connection with the Offering, the Company entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors. Pursuant to the Purchase Agreement, the Company agreed not to issue, enter into any agreement to issue or announce the issuance or proposed issuance of any Ordinary Shares or any securities convertible into or exercisable or exchangeable for Ordinary Shares or file any registration statement or prospectus, or any amendment or supplement thereto for 30 days after the closing date of the Offering, subject to certain exceptions. In addition, the Company has agreed not to effect or enter into an agreement to effect any issuance of Ordinary Shares or any securities convertible into or exercisable or exchangeable for Ordinary Shares involving a variable rate transaction (as defined in the Purchase Agreement) until the one-year anniversary of the closing date of the Offering, subject to certain exceptions.

    The Purchase Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing, customary indemnification obligations of the Company, other obligations of the parties and termination provisions. The representations, warranties and covenants contained in the Purchase Agreement were made only for the purposes of such agreement and as of specific dates, were solely for the benefit of the parties to such agreement and may be subject to limitations agreed upon by the contracting parties.

    A holder will not have the right to exercise any portion of the Ordinary Warrants if the holder (together with its affiliates) would beneficially own in excess of 4.99% or 9.99%, as applicable, of the number of Ordinary Shares outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the Ordinary Warrants.

    Pursuant to an engagement agreement (as amended, the “Engagement Agreement”) with H.C. Wainwright & Co., LLC (the “Placement Agent”), the Company agreed to pay the Placement Agent in connection with the Offering (i) a cash fee equal to 7.0% of the aggregate gross proceeds received in the Offering, (ii) a management fee equal to 1.0% of the aggregate gross proceeds received in the Offering, (iii) a non-accountable expense allowance of $50,000, (iv) reimbursement of up to $100,000 for legal fees and expenses and other out of pocket expenses and (v) up to $15,950 for the clearing expenses.

    Also pursuant to the Engagement Agreement, the Company, in connection with the Offering, agreed to issue to the Placement Agent or its designees warrants (the “Placement Agent Warrants”) to purchase up to an aggregate of 240,000 Ordinary Shares (the “Placement Agent Warrant Shares”) (which represents 6.0% of the Ordinary Shares sold in the Offering). The Placement Agent Warrants have substantially the same terms as the Ordinary Warrants issued and sold in the Offering, except that the Placement Agent Warrants have an exercise price of $0.8125 per Ordinary Share (which represents 125% of the combined public offering price per Ordinary Share and accompanying Ordinary Warrant), and will expire on June 25, 2030.

    The Ordinary Shares, the Ordinary Warrants, the Ordinary Warrant Shares, the Placement Agent Warrants and the Placement Agent Warrant Shares were offered by the Company pursuant to a Registration Statement on Form S-1 (as amended, the “Registration Statement”) originally filed with the Securities and Exchange Commission (the “SEC”) on June 20, 2025, as amended by Amendment No. 1 to Form S-1 (including the prospectus forming a part of such Registration Statement), under the Securities Act (File No. 333-288172), and declared effective by the SEC on June 25, 2025.

    The foregoing descriptions of the Purchase Agreement, the Ordinary Warrants and the Placement Agent Warrants are not complete and are qualified in their entirety by reference to the full text of the form of Purchase Agreement, the form of Ordinary Warrant, and the form of Placement Agent Warrant, copies of which are filed as Exhibits 10.1, 4.1 and 4.2, respectively, to this Current Report on Form 8-K and are incorporated herein by reference.


    Item 9.01 Financial Statements and Exhibits

    (d) Exhibits

    Exhibit No.
     
    Description
         
    4.1

    Form of Ordinary Warrant.
    4.2

    Form of Placement Agent Warrant.
    10.1+

    Form of Securities Purchase Agreement.
         
    104
     
    Cover Page Interactive Data File (embedded within the Inline XBRL document).

    + Schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company undertakes to furnish supplemental copies of any of the omitted schedules upon request by the U.S. Securities and Exchange Commission.



    SIGNATURES
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
     
     
    Lifeward Ltd.
     
     
     
     
     
    Dated: June 26, 2025
    By:
    /s/ Mike Lawless
     
     
    Name:
    Mike Lawless
     
     
    Title:
    Chief Financial Officer
     


    Get the next $LFWD alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LFWD

    DatePrice TargetRatingAnalyst
    2/10/2025$10.00Buy
    Laidlaw
    More analyst ratings

    $LFWD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Laidlaw initiated coverage on Lifeward with a new price target

    Laidlaw initiated coverage of Lifeward with a rating of Buy and set a new price target of $10.00

    2/10/25 7:00:44 AM ET
    $LFWD
    Industrial Specialties
    Health Care

    $LFWD
    Financials

    Live finance-specific insights

    View All

    Lifeward Ltd. Reports Second Quarter 2025 Financial Results

    Achieves record number of ReWalk systems placed for Medicare beneficiaries since fee schedule established Third consecutive quarter of U.S. ReWalk pipeline growth with over 130 qualified leads in process Appoints new CEO and CFO to spearhead strategic change and accelerate growth MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Aug. 14, 2025 (GLOBE NEWSWIRE) --  Lifeward Ltd., (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced its financial results for the three and six months ended June 30, 2025. Recent Highlights and Accomplishments for Lifeward Achieve

    8/14/25 8:00:00 AM ET
    $LFWD
    Industrial Specialties
    Health Care

    Lifeward to Report Second Quarter Financial Results on August 14, 2025

    MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that the Company will release its second quarter 2025 financial results before the markets open on Thursday, August 14, 2025. Mark Grant, President and Chief Executive Officer, and Almog Adar, Vice President of Finance, will host a conference call and live webcast at 8:30 a.m. EDT to discuss the financial results. To access the call, analysts and investors may utilize the following: Toll free (U.S.)1-833-316-05

    8/7/25 5:30:56 PM ET
    $LFWD
    Industrial Specialties
    Health Care

    Lifeward Ltd. Reports First Quarter 2025 Financial Results

    U.S. pipeline of ReWalk opportunities continues to build with over 120 qualified leads in process Closure of AlterG sites and resulting consolidation of resources and reduced expenditures yields improved operating expense trend Second consecutive quarter of AlterG revenue growth over 15% reflecting continued sales momentum MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, May 15, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced its financial results for the three months ended March 31, 2025. Recent Highlights and A

    5/15/25 8:00:33 AM ET
    $LFWD
    Industrial Specialties
    Health Care

    $LFWD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Lifeward Ltd. Reports Second Quarter 2025 Financial Results

    Achieves record number of ReWalk systems placed for Medicare beneficiaries since fee schedule established Third consecutive quarter of U.S. ReWalk pipeline growth with over 130 qualified leads in process Appoints new CEO and CFO to spearhead strategic change and accelerate growth MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Aug. 14, 2025 (GLOBE NEWSWIRE) --  Lifeward Ltd., (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced its financial results for the three and six months ended June 30, 2025. Recent Highlights and Accomplishments for Lifeward Achieve

    8/14/25 8:00:00 AM ET
    $LFWD
    Industrial Specialties
    Health Care

    Lifeward Names Almog Adar as New CFO, Strengthening Executive Leadership

    MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that Almog Adar, who previously served as the Company's Vice President of Finance and Chief Accounting Officer, has been appointed as the Company's new Chief Financial Officer. "I am thrilled to welcome Almog to the executive leadership team. He has been an invaluable leader within our finance team and brings thoughtful leadership and a strong commitment to supporting Lifeward's growth," said Mark Grant, Preside

    8/13/25 8:00:26 AM ET
    $LFWD
    Industrial Specialties
    Health Care

    Lifeward to Report Second Quarter Financial Results on August 14, 2025

    MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that the Company will release its second quarter 2025 financial results before the markets open on Thursday, August 14, 2025. Mark Grant, President and Chief Executive Officer, and Almog Adar, Vice President of Finance, will host a conference call and live webcast at 8:30 a.m. EDT to discuss the financial results. To access the call, analysts and investors may utilize the following: Toll free (U.S.)1-833-316-05

    8/7/25 5:30:56 PM ET
    $LFWD
    Industrial Specialties
    Health Care

    $LFWD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Turk Joseph E Jr bought $10,140 worth of Ordinary Shares (6,000 units at $1.69), increasing direct ownership by 48% to 18,516 units (SEC Form 4)

    4 - Lifeward Ltd. (0001607962) (Issuer)

    12/17/24 8:55:09 AM ET
    $LFWD
    Industrial Specialties
    Health Care

    Director Swinford Michael bought $43,858 worth of Ordinary Shares (21,622 units at $2.03), increasing direct ownership by 50% to 65,040 units (SEC Form 4)

    4 - Lifeward Ltd. (0001607962) (Issuer)

    11/27/24 8:03:53 AM ET
    $LFWD
    Industrial Specialties
    Health Care

    Director Swinford Michael bought $30,899 worth of Ordinary Shares (16,907 units at $1.83), increasing direct ownership by 64% to 43,418 units (SEC Form 4)

    4 - Lifeward Ltd. (0001607962) (Issuer)

    11/26/24 7:07:36 AM ET
    $LFWD
    Industrial Specialties
    Health Care

    $LFWD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Financial Officer Adar Almog

    4 - Lifeward Ltd. (0001607962) (Issuer)

    8/13/25 5:44:12 PM ET
    $LFWD
    Industrial Specialties
    Health Care

    Director Richner Randel was granted 35,920 units of Ordinary Shares (SEC Form 4)

    4 - Lifeward Ltd. (0001607962) (Issuer)

    8/7/25 6:14:06 PM ET
    $LFWD
    Industrial Specialties
    Health Care

    Director Levy Hadar was granted 35,920 units of Ordinary Shares (SEC Form 4)

    4 - Lifeward Ltd. (0001607962) (Issuer)

    8/7/25 6:13:51 PM ET
    $LFWD
    Industrial Specialties
    Health Care

    $LFWD
    SEC Filings

    View All

    SEC Form 10-Q filed by Lifeward Ltd.

    10-Q - Lifeward Ltd. (0001607962) (Filer)

    8/14/25 9:43:16 AM ET
    $LFWD
    Industrial Specialties
    Health Care

    Lifeward Ltd. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Lifeward Ltd. (0001607962) (Filer)

    8/14/25 8:15:41 AM ET
    $LFWD
    Industrial Specialties
    Health Care

    Lifeward Ltd. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Lifeward Ltd. (0001607962) (Filer)

    8/13/25 8:15:36 AM ET
    $LFWD
    Industrial Specialties
    Health Care

    $LFWD
    Leadership Updates

    Live Leadership Updates

    View All

    MedRhythms Appoints Larry Jasinski as Chief Executive Officer to Lead Next Phase of Growth and Commercial Expansion

    Industry veteran with proven track record in neurorehabilitation and fundraising to lead next phase of growth; Co-founder Brian Harris transitions to Chief Scientific Officer PORTLAND, Maine, July 7, 2025 /PRNewswire/ -- MedRhythms, Inc., a company pioneering the development of next-generation neurotherapeutics to improve walking, mobility and related functional outcomes, and creator of the world's first prescription music platform, announced the appointment of Larry Jasinski as Chief Executive Officer, effective immediately. Co-founder of MedRhythms, Brian Harris, who led the company through product development, successful clinical trials, listing product with the Food and Drug Administrati

    7/7/25 11:00:00 AM ET
    $LFWD
    Industrial Specialties
    Health Care

    Lifeward Names Mark Grant as New CEO

    MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, May 19, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that Mark Grant has been appointed as the Company's new President and Chief Executive Officer, effective June 2, 2025. Larry Jasinski, Lifeward's outgoing CEO, will serve as Co-CEO and, as previously announced, will serve in an advisory capacity until the end of June to assist with the transition, and thereafter on an as-needed basis through the end of 2025. "Mark brings 30 years of combined experience in commercia

    5/19/25 8:30:00 AM ET
    $LFWD
    Industrial Specialties
    Health Care

    Lifeward Announces Appointment of Robert J. Marshall to Its Board of Directors

    MARLBOROUGH, Mass. and YOKNEAM ILIT, Israel, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global market leader delivering life-changing solutions in physical rehabilitation and recovery, announced the Board of Directors has approved the appointment of Robert J. Marshall Jr. as a new director effective November 2, 2024. As part of his duties as a director, Mr. Marshall will serve as Chairman of the Audit Committee. Mr. Marshall has had a long and accomplished finance career in the medical device industry. Currently, Mr. Marshall serves as the Chief Financial Officer and Treasurer of Lantheus Holdings, Inc., a publicly traded radiopharmaceut

    11/7/24 4:05:14 PM ET
    $LFWD
    Industrial Specialties
    Health Care